What's New

Schizophrenia Drug Reduces Tau Protein Aggregation in Cell and Mouse Models, Study Finds

Amisulpride, an antipsychotic drug, is capable of reducing aggregation of the tau protein in cell and mouse models, according to a study published earlier this year. While the drug could…

Read More about Schizophrenia Drug Reduces Tau Protein Aggregation in Cell and Mouse Models, Study Finds

Duke Caregiver Community Event — September 7, 2023

AFTD Ambassador Jerry Lazarus and former AFTD Board member and support group facilitator Paul Lester will be hosting an AFTD exhibitor table at the Duke Caregiver Community Event in Durham,…

Read More about Duke Caregiver Community Event — September 7, 2023

Advancing Hope: AFTD’s Director of Research Engagement Attends Cure VCP Conference

Shana Dodge, PhD, AFTD’s Director of Research Engagement, spoke at the 2023 Cure VCP Connections Conference, held July 20-22 in Las Vegas. VCP disease, also called VCP-associated multisystem proteinopathy or…

Read More about Advancing Hope: AFTD’s Director of Research Engagement Attends Cure VCP Conference

Guest Feature: That Picture, That Movie, That Song – Connecting with My Dad Beyond FTD

FTD can distort one’s personality and behavior in unpredictable and upsetting ways, and it can be hard to remember who they were. But often, the “true” self of the person…

Read More about Guest Feature: That Picture, That Movie, That Song – Connecting with My Dad Beyond FTD

AFTD Webinar: Genetic FTD — To Test or Not to Test

The decision to learn one’s own genetic risk for developing FTD is highly personal. An individual’s test results may reveal information not only about their own status, but may shed…

Read More about AFTD Webinar: Genetic FTD — To Test or Not to Test

AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic

Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to develop a therapeutic to treat FTD-GRN (Frontotemporal Dementia caused by GRN gene mutation)…

Read More about AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic

Study Evaluates the Feasibility of ALLFTD’s Mobile App to Collect FTD Diagnostic Data

A study published in the journal Alzheimer’s and Dementia evaluates whether a mobile app developed by the multi-site FTD research consortium ALLFTD can help users record and transmit scientifically acceptable…

Read More about Study Evaluates the Feasibility of ALLFTD’s Mobile App to Collect FTD Diagnostic Data

Living Well with PPA

“Living Well with PPA” is a six-week online support program designed to provide a safe space so that people newly diagnosed with primary progressive aphasia can cope with their diagnosis…

Read More about Living Well with PPA

STAT Article Explores the Connection Between FTD and Visual Creativity

An article published by STAT explores the connection between the onset of FTD and a spike in visual creativity that a small percentage of people with the disease experience. The…

Read More about STAT Article Explores the Connection Between FTD and Visual Creativity

Advocacy Update: AFTD Ambassadors Offer Insights at July NAPA Meeting

At the most recent meeting of the National Alzheimer’s Project Act (NAPA) Advisory Council, AFTD Ambassadors Katie Zenger and Terry Walter shared their experiences to help educate federal officials on the needs and concerns…

Read More about Advocacy Update: AFTD Ambassadors Offer Insights at July NAPA Meeting